<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36943516</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>270</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>COVID19-associated new-onset movement disorders: a follow-up study.</ArticleTitle><Pagination><StartPage>2409</StartPage><EndPage>2415</EndPage><MedlinePgn>2409-2415</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-023-11661-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Neurological symptoms are common manifestation in acute COVID-19. This includes hyper- and hypokinetic movement disorders. Data on their outcome, however, is limited.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Cases with new-onset COVID-19-associated movement disorders were identified by searching the literature. Authors were contacted for outcome data which were reviewed and analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Movement disorders began 12.6&#xa0;days on average after the initial onset of COVID-19. 92% of patients required hospital admission (mean duration 23&#xa0;days). In a fraction of patients (6 of 27; 22%; 4 males/2 females, mean age 66.8&#xa0;years) the movement disorder (ataxia, myoclonus, tremor, parkinsonism) was still present after a follow-up period of 7.5&#x2009;&#xb1;&#x2009;3&#xa0;weeks. Severe COVID-19 in general and development of encephalopathy were risk factors, albeit not strong predictors, for the persistence.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The prognosis of new-onset COVID-19-associated movement disorder appears to be generally good. The majority recovered without residual symptoms within several weeks or months. Permanent cases may be due to unmasking of a previous subclinical movement disorder or due to vascular/demyelinating damage. Given the relatively low response rate of one third only and the heterogeneity of mechanisms firm conclusions on the (long-term) outome cannot, however, be drawn.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Susanne A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0001-7283-1995</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Ludwig Maximilians University Munich, Marchioninistr. 15, 81377, Munich, Germany. susanne.schneider@med.uni-muenchen.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desai</LastName><ForeName>Soaham</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Shree Krishna Hospital, Pramukhswami Medical College, Bhaikaka University, Karamsad, Anand, Gujarat, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phokaewvarangkul</LastName><ForeName>Onanong</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Chulalongkorn Centre of Excellence for Parkinson's Disease and Related Disorders, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, 1873 Rama 4 Road, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosca</LastName><ForeName>Elena Cecilia</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sringean</LastName><ForeName>Jirada</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Chulalongkorn Centre of Excellence for Parkinson's Disease and Related Disorders, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, 1873 Rama 4 Road, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anand</LastName><ForeName>Pria</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Departments of Neurology, Neurosurgery, and Medicine Boston University School of Medicine and Boston Medical Center, Boston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bravo</LastName><ForeName>Gary &#xc1;lvarez</ForeName><Initials>G&#xc1;</Initials><AffiliationInfo><Affiliation>Neuroimmunology and Multiple Sclerosis Unit of Girona, University Hospital Dr. Josep Trueta of Girona, Girona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cardoso</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Movement Disorders Unit, Neurology Service, Internal Medicine Department, UFMG, Belo Horizonte, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cervantes-Arslanian</LastName><ForeName>Anna M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Departments of Neurology, Neurosurgery, and Medicine Boston University School of Medicine and Boston Medical Center, Boston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chovatiya</LastName><ForeName>Harshad</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Shree Krishna Hospital, Pramukhswami Medical College, Bhaikaka University, Karamsad, Anand, Gujarat, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crosiers</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health Sciences, Translational Neurosciences, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Antwerp University Hospital, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dijkstra</LastName><ForeName>Femke</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health Sciences, Translational Neurosciences, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Antwerp University Hospital, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fearon</LastName><ForeName>Conor</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Neurology, Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital - UHN, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grandas</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Movement Disorders Unit, Neurology Department, Hospital General Universitario Gregorio Mara&#xf1;&#xf3;n, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guedj</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institut Fresnel, Nuclear Medicine Department, Aix Marseille Univ, APHM, CNRS, Centrale Marseille, Timone Hospital, CERIMED, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xe9;ndez-Guerrero</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurology Department, Hospital 12 de Octubre, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassan</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jankovic</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>Anthony E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Division of Neurology, Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital - UHN, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makhoul</LastName><ForeName>Karim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muccioli</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Shea</LastName><ForeName>Sarah A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostovan</LastName><ForeName>Vahid Reza</ForeName><Initials>VR</Initials><AffiliationInfo><Affiliation>Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perez-Sanchez</LastName><ForeName>Javier Ricardo</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Movement Disorders Unit, Neurology Department, Hospital General Universitario Gregorio Mara&#xf1;&#xf3;n, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramdhani</LastName><ForeName>Ritesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ros-Castell&#xf3;</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Neurology Department, Ramon y Cajal University Hospital, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schulte</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Departmemt of Neurology and Neurorehabilitation, Hospital Zum Heiligen Geist, Academic Teaching Hospital of the Heinrich-Heine-University Duesseldorf, Kempen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Priyank</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Privya Neurology Clinic, Ahmedabad, Gujarat, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wojtecki</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Departmemt of Neurology and Neurorehabilitation, Hospital Zum Heiligen Geist, Academic Teaching Hospital of the Heinrich-Heine-University Duesseldorf, Kempen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Neuroscience and Medical Psychology, Medical Faculty, Heinrich-Heine-University D&#xfc;sseldorf, D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pal</LastName><ForeName>Pramod Kumar</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, Karnataka, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009069" MajorTopicYN="Y">Movement Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014202" MajorTopicYN="N">Tremor</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID</Keyword><Keyword MajorTopicYN="N">Long covid</Keyword><Keyword MajorTopicYN="N">Movement disorder</Keyword><Keyword MajorTopicYN="N">Myoclonus ataxia</Keyword><Keyword MajorTopicYN="N">Outcome</Keyword><Keyword MajorTopicYN="N">Parkinsonism</Keyword><Keyword MajorTopicYN="N">Sars-CoV2</Keyword></KeywordList><CoiStatement>None of the authors report any conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>21</Day><Hour>12</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36943516</ArticleId><ArticleId IdType="pmc">PMC10029788</ArticleId><ArticleId IdType="doi">10.1007/s00415-023-11661-x</ArticleId><ArticleId IdType="pii">10.1007/s00415-023-11661-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Karuppan MKM, Devadoss D, Nair M, Chand HS, Lakshmana MK. SARS-CoV-2 infection in the central and peripheral nervous system-associated morbidities and their potential mechanism. Mol Neurobiol. 2021 doi: 10.1007/s12035-020-02245-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-020-02245-1</ArticleId><ArticleId IdType="pmc">PMC7805264</ArticleId><ArticleId IdType="pubmed">33439437</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider SA, Hennig A, Martino D. Relationship between COVID-19 and movement disorders: a narrative review. Eur J Neurol. 2022;29:1243&#x2013;1253. doi: 10.1111/ene.15217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15217</ArticleId><ArticleId IdType="pubmed">34918437</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadakar N, Ghaemmaghami S, Masoompour SM, et al. A First case of acute cerebellitis associated with coronavirus disease (COVID-19): a case report and literature review. Cerebellum. 2020;19:911&#x2013;914. doi: 10.1007/s12311-020-01177-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12311-020-01177-9</ArticleId><ArticleId IdType="pmc">PMC7393247</ArticleId><ArticleId IdType="pubmed">32737799</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan JL, Murphy KA, Sarna JR. Myoclonus and cerebellar ataxia associated with COVID-19: a case report and systematic review. J Neurol. 2021;268:3517&#x2013;3548. doi: 10.1007/s00415-021-10458-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10458-0</ArticleId><ArticleId IdType="pmc">PMC7897737</ArticleId><ArticleId IdType="pubmed">33616739</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimaldi S, Lagarde S, Harle JR, Boucraut J, Guedj E. Autoimmune encephalitis concomitant with SARS-CoV-2 infection: insight from (18)F-FDG PET imaging and neuronal autoantibodies. J Nucl Med. 2020;61:1726&#x2013;1729. doi: 10.2967/jnumed.120.249292.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.120.249292</ArticleId><ArticleId IdType="pmc">PMC8679632</ArticleId><ArticleId IdType="pubmed">32709734</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanguinetti SY, Ramdhani RA. Opsoclonus-myoclonus-ataxia syndrome related to the novel coronavirus (COVID-19) J Neuroophthalmol. 2021;41:e288&#x2013;e289. doi: 10.1097/WNO.0000000000001129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WNO.0000000000001129</ArticleId><ArticleId IdType="pmc">PMC8366529</ArticleId><ArticleId IdType="pubmed">32925477</ArticleId></ArticleIdList></Reference><Reference><Citation>Muccioli L, Rondelli F, Ferri L, Rossini G, Cortelli P, Guarino M. Subcortical myoclonus in coronavirus disease 2019: comprehensive evaluation of a patient. Mov Disord Clin Pract. 2020;7:971&#x2013;973. doi: 10.1002/mdc3.13046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mdc3.13046</ArticleId><ArticleId IdType="pmc">PMC7436730</ArticleId><ArticleId IdType="pubmed">32837963</ArticleId></ArticleIdList></Reference><Reference><Citation>Dijkstra F, Van den Bossche T, Willekens B, Cras P, Crosiers D. Myoclonus and cerebellar ataxia following COVID-19. Mov Disord Clin Pract. 2020;7:974&#x2013;976. doi: 10.1002/mdc3.13049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mdc3.13049</ArticleId><ArticleId IdType="pmc">PMC7436437</ArticleId><ArticleId IdType="pubmed">32837962</ArticleId></ArticleIdList></Reference><Reference><Citation>Ros-Castello V, Quereda C, Lopez-Sendon J, Corral I. Post-hypoxic myoclonus after COVID-19 infection recovery. Mov Disord Clin Pract. 2020;7:983&#x2013;984. doi: 10.1002/mdc3.13025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mdc3.13025</ArticleId><ArticleId IdType="pmc">PMC7404875</ArticleId><ArticleId IdType="pubmed">32837961</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann KM, Harmel J, Wojtecki L. CORE-myoclonus syndrome: a proposed neurological initial manifestation of COVID-19. Mov Disord Clin Pract. 2021;8:637&#x2013;638. doi: 10.1002/mdc3.13196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mdc3.13196</ArticleId><ArticleId IdType="pmc">PMC8088086</ArticleId><ArticleId IdType="pubmed">33981806</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand P, Zakaria A, Benameur K, et al. Myoclonus in patients with coronavirus disease 2019: a multicenter case series. Crit Care Med. 2020;48:1664&#x2013;1669. doi: 10.1097/CCM.0000000000004570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000004570</ArticleId><ArticleId IdType="pmc">PMC7448712</ArticleId><ArticleId IdType="pubmed">32804787</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand P, Zhou L, Bhadelia N, Hamer DH, Greer DM, Cervantes-Arslanian AM. Neurologic findings among inpatients with COVID-19 at a safety-net US hospital. Neurol Clin Pract. 2021;11:e83&#x2013;e91. doi: 10.1212/CPJ.0000000000001031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/CPJ.0000000000001031</ArticleId><ArticleId IdType="pmc">PMC8032445</ArticleId><ArticleId IdType="pubmed">33842075</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez-Guerrero A, Laespada-Garcia MI, Gomez-Grande A, et al. Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection. Neurology. 2020;95:e2109&#x2013;e2118. doi: 10.1212/WNL.0000000000010282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010282</ArticleId><ArticleId IdType="pubmed">32641525</ArticleId></ArticleIdList></Reference><Reference><Citation>Makhoul K, Jankovic J. Parkinson's disease after COVID-19. J Neurol Sci. 2021;422:117331. doi: 10.1016/j.jns.2021.117331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2021.117331</ArticleId><ArticleId IdType="pmc">PMC9755718</ArticleId><ArticleId IdType="pubmed">33540185</ArticleId></ArticleIdList></Reference><Reference><Citation>Fearon C, Mikulis DJ, Lang AE. Parkinsonism as a sequela of SARS-CoV-2 infection: pure hypoxic injury or additional COVID-19-related response? Mov Disord. 2021;36:1483&#x2013;1484. doi: 10.1002/mds.28656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28656</ArticleId><ArticleId IdType="pmc">PMC8242400</ArticleId><ArticleId IdType="pubmed">34043246</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassan M, Syed F, Ali L et al (2021) Chorea as a presentation of SARS-CoV-2 encephalitis: a clinical case report. J Mov Disord 14:245&#x2013;247</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8490192</ArticleId><ArticleId IdType="pubmed">33706477</ArticleId></ArticleIdList></Reference><Reference><Citation>Mas Serrano M, Perez-Sanchez JR, Portela Sanchez S, et al. Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir. J Neurol Sci. 2020;415:116944. doi: 10.1016/j.jns.2020.116944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.116944</ArticleId><ArticleId IdType="pmc">PMC7255189</ArticleId><ArticleId IdType="pubmed">32531579</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavallieri F, Fioravanti V, Bove F et al (2022) COVID-19 and Parkinsonism: a critical appraisal. Biomolecules 12(7):970</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9313170</ArticleId><ArticleId IdType="pubmed">35883526</ArticleId></ArticleIdList></Reference><Reference><Citation>Hull M, Jankovic J (2021) Increased incidence of functional (psychogenic) movement disorders in children and adults amidst the COVID-19 pandemic: a cross-sectional study. Neurol Clin Pract (epub ahead of print)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8610548</ArticleId><ArticleId IdType="pubmed">34840884</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>